Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
clinical trials
life sciences
national blog main
national top stories
new york
3
×
new york blog main
new york top stories
san diego blog main
san diego top stories
abbvie
acorda therapeutics
akcea therapeutics
allergan
ampyra
anylam pharmaceuticals
apokyn
apomorphine
bristol-myers squibb
cardiomyopathy
clinical data
dalfampridine
drugs
duopa
genfit
gilead sciences
inbrija
inotersen
intercept pharmaceuticals
ldl-c
liver
liver disease
madrigal pharmaceuticals
mark pruzanski
mylan
nash
neuropathy
nonalcoholic steatohepatitis
obeticholic acid
What
approved
disease
3
×
drug
3
×
fda
new
patients
acorda
ago
akcea
alnylam
amyloidosis
attr
available
battle
cope
data
debilitating
episodes
fatty
friday
genetic
gets
help
horizon
intercept
known
late
liver
looms
marketed
meant
medications
medicine
medicines
nash
nod
nonalcoholic
oks
parkinson’s
pfizer
Language
Current search:
disease
×
drug
×
" new york "
×
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
With New Data, Intercept On Track for First-Ever Approved NASH Drug
@xconomy.com
5 years ago
Acorda Gets FDA Nod For New Parkinson’s Drug, But Rival Looms